TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29550383

Group type: EXPERIMENTAL
Intervention: BP1001 monotherapy (90 mg/m2)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: BP1001 monotherapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: BP1001 plus low-dose cytarabine
Number of subjects: 39
Study: 26836781

Group type: EXPERIMENTAL
Intervention: A+M (amoxicillin and metronidazole)
Number of subjects: 37

Group type: COMPARATOR
Intervention: SRP (scaling and root planing)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Az (Azithromycin)
Number of subjects: 37
Study: 24625583

Group type: EXPERIMENTAL
Intervention: 4 weeks of intramuscular streptomycin
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 8 weeks of intramuscular streptomycin
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 151
Study: 22694808

Group type: EXPERIMENTAL
Intervention: Submaximal velocity
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Maximal velocity
Number of subjects: 7
Study: 20214755

Group type: EXPERIMENTAL
Intervention: Initiation of antiretroviral therapy based on WHO clinical criteria
Number of subjects: 458

Group type: COMPARATOR
Intervention: WHO clinical stage 3
Number of subjects: 458

Group type: COMPARATOR
Intervention: WHO clinical stage 4
Number of subjects: 458
Study: 17373743

Group type: EXPERIMENTAL
Intervention: Sodium butyrate coated tablets (1 gram)
Number of subjects: 24
Study: 15814544

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 205

Group type: COMPARATOR
Intervention: Cyclosporin microemulsion (ME)
Number of subjects: 205
Study: 12351331

Group type: EXPERIMENTAL
Intervention: Resistance training (80% of 10RM) for 8 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Detraining after 8 weeks of resistance training
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 15
Study: 9527962

Group type: EXPERIMENTAL
Intervention: Long-chain triglycerides (LCT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Balanced emulsion of long- and medium-chain triglycerides (LCT/MCT)
Number of subjects: 33
Study: 8562036

Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP1) 1.0 mg/kg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP1) 2.0 mg/kg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP1) 0.5 mg/kg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP1) (all dosages)
Number of subjects: 41
Study: 2653713

Group type: EXPERIMENTAL
Intervention: 2 g of CTX every 6 hr
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 2 g of CTX every 8 hr
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 2 g of CTX every 12 hr
Number of subjects: 31
Study: 236806

Group type: EXPERIMENTAL
Intervention: AH 5158
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study: 31837393

Group type: EXPERIMENTAL
Intervention: Delta-4 fibrosis score (D4FS) derived from gamma-glutamyl transpeptidase (GGT), platelet count, alanine aminotransferase (ALT), and liver stiffness measurement (LSM)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Vibration-controlled transient elastography (VCTE)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: FIB-4
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: APRI
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: AAR
Number of subjects: 77
Study: 30222495

Group type: EXPERIMENTAL
Intervention: Sliding neural mobilization
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Tensioning neural mobilization
Number of subjects: 37
Study: 28952214

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy (LH) in obese patients
Number of subjects: 243

Group type: COMPARATOR
Intervention: Laparoscopic hysterectomy (LH) in non-obese patients
Number of subjects: 243
Study: 26527776

Group type: COMPARATOR
Intervention: LV5FU2 (bolus/infusional fluorouracil plus leucovorin)
Number of subjects: 2246

Group type: EXPERIMENTAL
Intervention: FOLFOX4 (LV5FU2 plus oxaliplatin)
Number of subjects: 2246

Group type: COMPARATOR
Intervention: LV5FU2
Number of subjects: 2246

Group type: EXPERIMENTAL
Intervention: FOLFOX4
Number of subjects: 2246
Study: 23835291

Group type: EXPERIMENTAL
Intervention: Single dose of zoledronic acid (ZA) given 1 week before beginning ADT (arm 1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Single dose of zoledronic acid (ZA) given 6 months after beginning ADT (arm 2)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Monthly administration of zoledronic acid (ZA) starting 6 months after beginning ADT for a total of 6 doses (arm 3)
Number of subjects: 44
Study: 21812904

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no celecoxib)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg and 400 mg
Number of subjects: 120
Study: 20139548

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (0.125% plain bupivacaine)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Parenteral opioid/sedative (pentazocine/promethazine)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Parenteral opioid/sedative
Number of subjects: 50
Study: 16751820

Group type: EXPERIMENTAL
Intervention: 40 minutes continuous brisk walking
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 4x10 minutes brisk walking
Number of subjects: 35

Group type: COMPARATOR
Intervention: no brisk walking
Number of subjects: 35
Study: 15542047

Group type: EXPERIMENTAL
Intervention: Handball group
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study: 12144644

Group type: EXPERIMENTAL
Intervention: Combination of sodium cromoglycate (SCG) and salbutamol (administered as a nebulized solution)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salbutamol (administered as a nebulized solution)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG) (administered as a nebulized solution)
Number of subjects: 0
Study: 9502092

Group type: EXPERIMENTAL
Intervention: Intra-oral sonography
Number of subjects: 15
Study: 7674693

Group type: EXPERIMENTAL
Intervention: Systematic approach to cardiac risk stratification including clinical evaluation, functional assessment, and surgical risk assessment.
Number of subjects: 0
Study: 2568645

Group type: EXPERIMENTAL
Intervention: Metaclazepam 15 mg per day
Number of subjects: 168

Group type: COMPARATOR
Intervention: Diazepam 15 mg per day
Number of subjects: 168
Study: 192441

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (oral or intravenous)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 21
Study: 31538430

Group type: EXPERIMENTAL
Intervention: Short-term exposure to PM10 (exceeding 100 μg/m³)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very short-term exposure to PM10 (exceeding 100 μg/m³ for 2 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term exposure to PM2.5 (exceeding 50 μg/m³)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very short-term exposure to PM2.5 (exceeding 50 μg/m³ for 2 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term PM10 exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term PM2.5 exposure
Number of subjects: 0
Study: 28324055

Group type: EXPERIMENTAL
Intervention: Fasting plus GH blockade (pegvisomant)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 9
Study: 26482691

Group type: EXPERIMENTAL
Intervention: Tailored nutritional guidance with home visits during one year
Number of subjects: 78

Group type: COMPARATOR
Intervention: Written guide about nutrition in older adults and community‐provided normal care (Control Group)
Number of subjects: 78
Study: 23109056

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (GCBT)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 196
Study: 22110219

Group type: EXPERIMENTAL
Intervention: Prolactin (PRL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Follicle Stimulating Hormone (FSH)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone (LH)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PRL/P+ ratio clustering
Number of subjects: 100
Study: 19552866

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 19923

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19923
Study: 17449505

Group type: EXPERIMENTAL
Intervention: Family based cognitive behaviour counselling programme of four sessions with a trained psychiatric nurse counsellor between three to six months after the suicide.
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Family based cognitive behaviour counselling programme
Number of subjects: 122
Study: 15333593

Group type: EXPERIMENTAL
Intervention: NuvaRing (21 subjects)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Combined oral contraceptive (COC) (19 subjects)
Number of subjects: 40
Study: 11530275

Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Haloperidol (10 mg/day)
Number of subjects: 27
Study: 9563738

Group type: EXPERIMENTAL
Intervention: Zileuton (600 mg, four times daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8169699

Group type: EXPERIMENTAL
Intervention: Cephalothin (1 g i.v. every 6 h for four doses)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 30925579

Group type: EXPERIMENTAL
Intervention: Surgical treatment for painful UBCs
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Artificial bone substitutes
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Intramedullary stabilization (eg, rodding)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Nonoperative treatment for painless UBCs
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Surgery for high fracture risk in painless UBCs
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Nonoperative treatment for fractured, nondisplaced and mildly displaced proximal humerus UBCs
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Nonoperative treatment for mildly displaced pathologic humerus shaft fractures
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Nonoperative treatment for severely displaced pathologic proximal humerus fractures
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Surgical treatment for severely displaced pathologic proximal humerus fractures
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Surgical treatment for severely displaced humerus shaft fractures
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Intramedullary stabilization for severely displaced humerus shaft fractures
Number of subjects: 400
Study: 31037789

Group type: EXPERIMENTAL
Intervention: PRISM intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 100
Study: 28007766

Group type: EXPERIMENTAL
Intervention: Lead shielding system
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Radiation protection drape
Number of subjects: 120

Group type: COMPARATOR
Intervention: No shielding
Number of subjects: 120
Study: 25522743

Group type: EXPERIMENTAL
Intervention: Dorsal group (EA to dorsal segmental acupuncture points BL18‐23 bilaterally)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Limb group (EA to points in the arms and legs LI10‐LI11, ST36‐Zongping)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ear group (EA to ear points in the cavum conchae)
Number of subjects: 16
Study: 23674159

Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 44
Study: 21864813

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PESs)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Bare metal stents (BMSs)
Number of subjects: 116
Study: 18450829

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 885

Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 885
Study: 16642224

Group type: EXPERIMENTAL
Intervention: Cooling the blood and invigorating blood circulation decoction
Number of subjects: 72

Group type: COMPARATOR
Intervention: Hepatocyte growth factor (HGF) 80-120 mg daily
Number of subjects: 72
Study: 12560956

Group type: EXPERIMENTAL
Intervention: Eccentric exercise (40 maximal eccentric contractions of the anterior tibial muscles at an angular velocity of 90 degrees s‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 10
Study: 10881805

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (300-mg bolus and 20 mg x kg(‐1) x day(‐1) for 3 days)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (150-mg bolus and 10 mg x kg(‐1) x day(‐1) for 3 days)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 9179578

Group type: EXPERIMENTAL
Intervention: Postponing Sexual Involvement (PSI) curriculum implemented by adult or youth leaders
Number of subjects: 10600

Group type: EXPERIMENTAL
Intervention: Postponing Sexual Involvement (PSI) curriculum
Number of subjects: 10600
Study: 7504824

Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3517075

Group type: EXPERIMENTAL
Intervention: 0.02% chlorhexidine (CH)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 0.05% metronidazole (MD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Inactive control (PL)
Number of subjects: 22
Study: 31470737

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF) measured by maximal cardiorespiratory stress test and peak oxygen uptake
Number of subjects: 109

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 109
Study: 29921245

Group type: EXPERIMENTAL
Intervention: Healthy dietary and hygiene behaviour intervention
Number of subjects: 0
Study: 26732827

Group type: EXPERIMENTAL
Intervention: 0.6ng/kg LPS
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 25212080

Group type: EXPERIMENTAL
Intervention: MF59‐adjuvanted, trivalent, influenza vaccine (ATIV)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Non‐adjuvanted, trivalent, influenza vaccine (TIV)
Number of subjects: 360
Study: 23188899

Group type: EXPERIMENTAL
Intervention: Cemented all‐polyethylene Ultima acetabular component (Group A)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Cementless porous‐coated acetabular component (Group B)
Number of subjects: 287
Study: 20172072

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.5 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 32
Study: 18793546

Group type: EXPERIMENTAL
Intervention: Epoetin-beta 6,000 IU (0.3 ml)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Darbepoetin-alpha 30 mg (0.3 ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16055640

Group type: EXPERIMENTAL
Intervention: Positive and negative religious (Christian) symbols presented outside of conscious awareness
Number of subjects: 0

Group type: COMPARATOR
Intervention: Similar images lacking Christian meaning
Number of subjects: 0
Study: 12150618

Group type: EXPERIMENTAL
Intervention: Topical budesonide (256 microg daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Topical budesonide
Number of subjects: 26
Study: 10541947

Group type: EXPERIMENTAL
Intervention: Phototherapy (24 hours exposure, wavelength 425-475 nm)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (untreated neonates)
Number of subjects: 50
Study: 7599840

Group type: EXPERIMENTAL
Intervention: 2 ppm NO during ZEEP
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 2 ppm NO during PEEP
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 2 ppm NO during ZEEP (no alveolar recruitment)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 2 ppm NO during PEEP (no alveolar recruitment)
Number of subjects: 21

Group type: COMPARATOR
Intervention: ZEEP
Number of subjects: 21

Group type: COMPARATOR
Intervention: 10 cm H2O PEEP
Number of subjects: 21
Study: 2089822

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 11

Group type: COMPARATOR
Intervention: NaCl 0.9% placebo
Number of subjects: 11
Study: 340492

Group type: EXPERIMENTAL
Intervention: Dialyzable transfer factor (TF)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Column purified transfer factor (TF)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Hypoxanthine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 33
Study: 31566307

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily
Number of subjects: 663

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily (UIP-like fibrotic pattern)
Number of subjects: 663

Group type: COMPARATOR
Intervention: Placebo (UIP-like fibrotic pattern)
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 663
Study: 29089019

Group type: EXPERIMENTAL
Intervention: Lotilaner (Credelio™) at a minimum recommended dose rate of 20 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lotilaner (Credelio™)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 0
Study: 26355167

Group type: EXPERIMENTAL
Intervention: 4.0 mm-long implants
Number of subjects: 150

Group type: COMPARATOR
Intervention: 8.5 mm-long implants
Number of subjects: 150
Study: 23801734

Group type: EXPERIMENTAL
Intervention: Cerebellar cortex excitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerebellar cortex inhibition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cerebellar cortex excitation and inhibition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioral parameters reflecting adaptation capacity
Number of subjects: 0
Study: 21368429

Group type: EXPERIMENTAL
Intervention: Rabdosia rubescens aqueous extract, 220 mL once a day for 30 days
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo, 220 mL once a day for 30 days
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Rabdosia rubescens aqueous extract
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 19142085

Group type: EXPERIMENTAL
Intervention: Carbohydrate‐rich drink (400 ml) at 6‐7 a.m.
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Overnight intravenous 5% glucose infusion (1000 ml)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Overnight fasting
Number of subjects: 210
Study: 18087557

Group type: EXPERIMENTAL
Intervention: BMSC (bone marrow mononuclear stem cells) group
Number of subjects: 42
Study: 15494915

Group type: EXPERIMENTAL
Intervention: 100 mg of coenzyme Q twice daily for 3 months
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 11215725

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mannitol
Number of subjects: 0
Study: 9391289

Group type: EXPERIMENTAL
Intervention: QTPEAK dispersion tertile (> or = 50 ms)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: QTPEAK dispersion tertile (> or = 50 ms) after adjustment for left ventricular hypertrophy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: QTEND dispersion in pre-event ECGs
Number of subjects: 72

Group type: COMPARATOR
Intervention: QT dispersion in baseline ECG
Number of subjects: 72
Study: 8350435

Group type: EXPERIMENTAL
Intervention: Cell Saver Autotransfusion Device (n = 18)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No Cell Saver Autotransfusion Device (n = 18)
Number of subjects: 96
Study: 3737440

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Codeine phosphate 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of acetaminophen 1000 mg and codeine phosphate 60 mg
Number of subjects: 0
Study: 31651355

Group type: EXPERIMENTAL
Intervention: Sahaj Samadhi meditation (SSM)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP)
Number of subjects: 192
Study: 29154277

Group type: EXPERIMENTAL
Intervention: 100 mg twice a day
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: 4 mg twice a day (monotherapy)
Number of subjects: 800

Group type: COMPARATOR
Intervention: 4 mg twice a day (add-on therapy)
Number of subjects: 800
Study: 27181733

Group type: EXPERIMENTAL
Intervention: $AFE (Money Management Intervention)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 144
Study: 24457999

Group type: EXPERIMENTAL
Intervention: beta-alanine (6.4 g/day for 6 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo (6.4 g/day for 6 weeks)
Number of subjects: 27
Study: 23183517

Group type: EXPERIMENTAL
Intervention: n‐3 PUFA (eicosapentaenoic and docosahexaenoic acid ethyl esters, 3.0 g/d)
Number of subjects: 60
Study: 20647406

Group type: EXPERIMENTAL
Intervention: Patient support and navigation intervention (one call from a professional health worker and multiple calls from a lay health worker)
Number of subjects: 1708

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1708
Study: 17445403

Group type: EXPERIMENTAL
Intervention: Transballoon ultrasound ablation catheter during mitral valve replacement surgery
Number of subjects: 21
Study: 15823787

Group type: EXPERIMENTAL
Intervention: Simultaneous intervention for physical activity and fat intake
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Sequential intervention for physical activity followed by fat intake
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Sequential intervention for fat intake followed by physical activity
Number of subjects: 771

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 771
Study: 11994339

Group type: EXPERIMENTAL
Intervention: DHEA (30 mg/d if <45 yr of age and 20 mg if >=45 yr of age) for 6 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 9920063

Group type: EXPERIMENTAL
Intervention: Naloxone (125 microg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 60